Patents by Inventor Danilo R. Casimiro
Danilo R. Casimiro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240156952Abstract: Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.Type: ApplicationFiled: July 18, 2023Publication date: May 16, 2024Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
-
Patent number: 11752206Abstract: Herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.Type: GrantFiled: March 15, 2018Date of Patent: September 12, 2023Assignee: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
-
Patent number: 11406706Abstract: The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and/or cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.Type: GrantFiled: September 24, 2020Date of Patent: August 9, 2022Assignee: Merck Sharp & Dohme LLCInventors: Marian Gindy, Danilo R. Casimiro, Andrew Bett, Jan H. Ter Meulen
-
Publication number: 20210002813Abstract: The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and/or cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.Type: ApplicationFiled: September 24, 2020Publication date: January 7, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Marian Gindy, Danilo R. Casimiro, Andrew Bett, Jan H. Ter Meulen
-
Patent number: 10821175Abstract: The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.Type: GrantFiled: February 23, 2015Date of Patent: November 3, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Marian Gindy, Danilo R. Casimiro, Andrew Bett, Jan H. Ter Meulen
-
Publication number: 20200129615Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. In a preferred embodiment, the vaccine is formulated as a lipid nanoparticle comprising at least one cationic lipid.Type: ApplicationFiled: March 15, 2018Publication date: April 30, 2020Applicant: ModernaTX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
-
Publication number: 20200054737Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: April 25, 2018Publication date: February 20, 2020Applicant: Modema TX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
-
Patent number: 10449243Abstract: The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine comprises at least one live, 5 attenuated dengue virus or live, attenuated chimeric dengue virus and the second dengue vaccine is a recombinant dengue subunit vaccine, a DNA vaccine, a conjugate vaccine, or an inactivated dengue vaccine; wherein the genome of the live attenuated dengue virus or the live attenuated chimeric dengue virus comprises a 30 nucleotide deletion of the TL2 stem-loop structure of the 3? untranslated region. The dengue virus vaccine compositions of the invention may further 10 comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent.Type: GrantFiled: December 18, 2015Date of Patent: October 22, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Danilo R. Casimiro, Andrew Bett, Beth-Ann Griswold Coller, Govindarajan Dhanasekaran, Ramesh V. Chintala
-
Publication number: 20180303929Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: October 21, 2016Publication date: October 25, 2018Applicant: Moderna TX, Inc.Inventors: Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro
-
Publication number: 20170360917Abstract: The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine comprises at least one live, 5 attenuated dengue virus or live, attenuated chimeric dengue virus and the second dengue vaccine is a recombinant dengue subunit vaccine, a DNA vaccine, a conjugate vaccine, or an inactivated dengue vaccine; wherein the genome of the live attenuated dengue virus or the live attenuated chimeric dengue virus comprises a 30 nucleotide deletion of the TL2 stem-loop structure of the 3? untranslated region. The dengue virus vaccine compositions of the invention may further 10 comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent.Type: ApplicationFiled: December 18, 2015Publication date: December 21, 2017Applicant: Merck Sharp & Dohme Corp.Inventors: Danilo R. Casimiro, Andrew Bett, Beth-Ann Griswold Coller, Govindarajan Dhanasekaran, Ramesh V. Chintala
-
Publication number: 20160361411Abstract: The instant invention provides for novel lipid nanoparticle (LNP) formulations, containing cationic lipids, for use as vaccine adjuvants and/or as antigen delivery systems. It is an object of the instant invention to provide LNP formulations that demonstrate enhancements in humoral and cellular immunogenicity of vaccine antigens, particularly subunit vaccine antigens, when utilized alone or in combination with immunostimulatory agents (e.g. small molecule or oligonucleotide TLR agonists). The instant invention further identifies physical and chemical properties of the LNP formulations that can be manipulated to enhance antigen efficiency and adjuvant tolerability in vivo.Type: ApplicationFiled: February 23, 2015Publication date: December 15, 2016Applicant: Merck Sharp & dohme CorpInventors: Marian Gindy, Danilo R. Casimiro, Andrew Bett, Jan H. Ter Meulen
-
Publication number: 20120121630Abstract: The present invention provides Herpes Simplex Virus (HSV) gD, gC, gB and/or gE recombinant glycoproteins having a particular pre-selected N-linked glycosylation pattern as the predominant N-glycoform. The present invention also provides methods of producing these recombinant glycoproteins in yeast, preferably Pichia pastoris, which may be glycoengineered to provide particular glycosylation patterns. The present invention further provides vaccines comprising gD and gC, and optionally gB and/or gE, at least one of which has a particular pre-selected N-linked glycosylation pattern as the predominant N-glycoform. The recombinant glycoproteins are produced by a method which, in one embodiment, comprises transforming a yeast of the genus Pichia with an expression vector containing a DNA encoding an HSV glycoprotein, which is under regulation of a promoter functional in a yeast of the genus Pichia, culturing the yeast in a medium, and recovering the recombinant glycoprotein from the obtained culture.Type: ApplicationFiled: July 21, 2010Publication date: May 17, 2012Inventors: Janine T. Bryan, John W. Ballet, Jessica A. Flynn, Danilo R. Casimiro, Robert C. Davidson, Victoria Copeland, Sandra E. Rios, Byung-Kwon Choi, Stefan Wildt
-
Patent number: 8168757Abstract: The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.Type: GrantFiled: March 3, 2009Date of Patent: May 1, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Adam C. Finnefrock, Tong-Ming Fu, Daniel C. Freed, Danilo R. Casimiro, Fengsheng Li, Aimin Tang
-
Publication number: 20110136896Abstract: The present invention relates to compositions and methods to elicit or enhance cell-mediated immunity against HCMV infection by providing polynucleotides encoding variant HCMV pp65, IE1, and IE2 proteins, and fusion proteins thereof. The present invention also provides recombinant vectors including, but not limited to, adenovirus and plasmid vectors comprising said polynucleotides and host cells comprising said recombinant vectors. Also provided herein are purified forms of the variant HCMV pp65, IE1, and IE2 proteins described herein, and fusion proteins. The variant HCMV proteins, and fusion proteins thereof, are useful as vaccines for the protection from and/or treatment of HCMV infection. Said vaccines are useful as a monotherapy or a part of a therapeutic regime, said regime comprising administration of a second vaccine such as a polynucleotide, cell-based, protein or peptide-based vaccine.Type: ApplicationFiled: July 28, 2009Publication date: June 9, 2011Inventors: Tong-Ming Fu, Danilo R. Casimiro, Daniel C. Freed, Aimin Tang
-
Publication number: 20110008369Abstract: The present invention features PD-1 binding proteins, a subset of which inhibits binding of PD-L1 to the PD-1 receptor. These binding proteins can be employed to modulate the immune system through the manipulation of the PD-1 signaling pathway, enhancing host immunity to treat infections and cancer.Type: ApplicationFiled: March 3, 2009Publication date: January 13, 2011Inventors: Adam C. Finnefrock, Tong-Ming Fu, Daniel C. Freed, Danilo R. Casimiro, Fengsheng Li, Aimin Tang
-
Publication number: 20100183651Abstract: A novel method for generating vaccine sequences is disclosed herein that preserves contiguous epitope length stretches of amino acids or nucleotides from an input pool of sequences. The method generates continuous, stepwise epitope consensus that together provides for a single globally optimized sequence. The end sequences are designed to maximize overlap between any potential epitope length sequence extract from a natural antigen sequence. The disclosed method, thus, allows one to maximize the number of potential natural epitopes that are mimicked in a resultant vaccine sequence. Various representative HIV vaccine sequences have been generated and are disclosed herein.Type: ApplicationFiled: March 26, 2008Publication date: July 22, 2010Inventors: Adam C. Finnefrock, Danilo R. Casimiro, Jon H. Condra, John W. Shiver, Andrew J. Bett
-
Publication number: 20080254059Abstract: Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g., fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 26, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for delivery and expression of heterologous genes are provided.Type: ApplicationFiled: February 7, 2006Publication date: October 16, 2008Inventors: Andrew J. Bett, Danilo R. Casimiro, John W. Shiver, Emilio A. Emini, Michael Chastain, David C. Kaslow
-
Publication number: 20040191222Abstract: Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g, fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 34, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for the delivery and expression of exogenous genes are provided.Type: ApplicationFiled: August 21, 2003Publication date: September 30, 2004Inventors: Emilio A. Emini, John W. Shiver, Andrew J. Bett, Danilo R. Casimiro, David C. Kaslow, Michael Chastain
-
Publication number: 20040185555Abstract: Adenoviral serotypes differ in their natural tropism. The various serotypes of adenovirus have been found to differ in at least their capsid proteins (e.g., penton-base and hexon proteins), proteins responsible for cell binding (e.g, fiber proteins), and proteins involved in adenovirus replication. This difference in tropism and capsid proteins among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins. The present invention bypasses such requirement for capsid protein modification as it presents a recombinant, replication-defective adenovirus of serotype 24, a rare adenoviral serotype, and methods for generating the alternative, recombinant adenovirus. Additionally, means of employing the recombinant adenovirus for the delivery and expression of exogenous genes are provided.Type: ApplicationFiled: August 21, 2003Publication date: September 23, 2004Inventors: Emilio A. Emini, John W. Shiver, Andrew J. Bett, Danilo R. Casimiro, Michael Chastain, David C. Kaslow, Manal Morsy
-
Patent number: 6787351Abstract: An adenoviral vector is described which carries a codon-optimized gag gene, along with a heterologous promoter and transcription terminator. This viral vaccine can effectively prevent HIV infection when administered to humans either alone or as part of a prime and boost regime also with a vaccine plasmid.Type: GrantFiled: March 27, 2001Date of Patent: September 7, 2004Assignee: Merck & Co., Inc.Inventors: Ling Chen, John W. Shiver, Andrew J. Bett, Danilo R. Casimiro, Michael J. Caulfield, Michael A. Chastain, Emilio A. Emini